Clinical Trials
3 trialsNCT04614636 2023-09-21
FT538 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT03023527 2018-05-23
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
PETHEMA Foundation
Phase 1 Terminated
NCT00726869 2012-08-23
A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
Abbott
Phase 1 Terminated